AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Condom Barriers Scale scores
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Being unmarried
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minority status
Number of subjects: 324
Study 16791111 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using a standardized family member, including formal teaching of a communication framework and practice session.
Number of subjects: 106
Study 16791111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 106
Study 16117969 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishmanin skin test (LST)
Number of subjects: 59
Study 16117969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (merthiolate‐phosphate‐buffered saline)
Number of subjects: 59
Study 10760830 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x CMF + RT
Number of subjects: 199
Study 10760830 — intervention group
Group type: COMPARATOR
Intervention: 6 x CMF
Number of subjects: 199
Study 9323505 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 2 liter daily exchange
Number of subjects: 117
Study 9323505 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 daily exchanges
Number of subjects: 117
Study 9323505 — intervention group
Group type: COMPARATOR
Intervention: Kt/V < 1.7
Number of subjects: 117
Study 9323505 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V > or = 1.7
Number of subjects: 117
Study 9323505 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 117
Study 8405010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 80 mg q.i.d.
Number of subjects: 0
Study 8405010 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 3898970 — intervention group
Group type: EXPERIMENTAL
Intervention: POII cefamandole (2g)
Number of subjects: 250
Study 3898970 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 31667338 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + Dasatinib (100 mg/day PO)
Number of subjects: 120
Study 31667338 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/day PO)
Number of subjects: 120
Study 31667338 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Letrozole + Dasatinib
Number of subjects: 120
Study 30742373 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg, twice a day for 12 weeks
Number of subjects: 296
Study 30742373 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg, twice a day for 12 weeks
Number of subjects: 296
Study 27514861 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard port location (Task A)
Number of subjects: 0
Study 27514861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified port location (Task B)
Number of subjects: 0
Study 27514861 — intervention group
Group type: COMPARATOR
Intervention: Group I (Task A → Task B)
Number of subjects: 0
Study 27514861 — intervention group
Group type: COMPARATOR
Intervention: Group II (Task B → Task A)
Number of subjects: 0
Study 24129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced REP
Number of subjects: 384
Study 24129806 — intervention group
Group type: COMPARATOR
Intervention: Standard REP
Number of subjects: 384
Study 22520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at 6, 10, and 14 weeks of age
Number of subjects: 6674
Study 22520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV), RotaTeq(®)
Number of subjects: 6674
Study 20177759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle ablation approach (Group 2)
Number of subjects: 60
Study 20177759 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomical approach (Group 1)
Number of subjects: 60
Study 18664319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 4983
Study 15914134 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM gel (2 mL applied at bedtime for 7 consecutive days)
Number of subjects: 36
Study 15914134 — intervention group
Group type: COMPARATOR
Intervention: K-Y Jelly Personal Lubricant (control group)
Number of subjects: 36
Study 11823086 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient management program
Number of subjects: 200
Study 11823086 — intervention group
Group type: COMPARATOR
Intervention: Usual care (nonintervention group)
Number of subjects: 200
Study 9614476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure treatment
Number of subjects: 170
Study 9614476 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation treatment
Number of subjects: 170
Study 9614476 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 170
Study 8714922 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour/8-hour clinical groups
Number of subjects: 93
Study 8714922 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour/5-hour clinical groups
Number of subjects: 93
Study 8714922 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 93
Study 2527971 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (doses of 20 to 400 mg/d)
Number of subjects: 0
Study 2527971 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound plasma toremifene and its metabolites
Number of subjects: 0
Study 2527971 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (in the presence of toremifene)
Number of subjects: 0
Study 7588 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacetazine
Number of subjects: 50
Study 7588 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 50
Study 31190607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning based on fully convolutional neural network (FCNN) for segmenting brain tissues including T2-hyperintense MS lesions.
Number of subjects: 1000
Study 27043224 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg, t.i.d.)
Number of subjects: 50
Study 27043224 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg, t.i.d.)
Number of subjects: 50
Study 25927692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hoc tailored nursing intervention providing information and emotional support
Number of subjects: 436
Study 25927692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 436
Study 25927692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hoc tailored nursing intervention
Number of subjects: 436
Study 23204049 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial probands with IAs
Number of subjects: 323
Study 21897774 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with position monitoring and supine alarm device
Number of subjects: 15
Study 21897774 — intervention group
Group type: COMPARATOR
Intervention: Inactive treatment (control)
Number of subjects: 15
Study 19567759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 19567759 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 19567759 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 16485885 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities including chemopreventative, chemotherapeutic, destructive, and novel immunologic methods.
Number of subjects: 0
Study 15110128 — intervention group
Group type: COMPARATOR
Intervention: Statin use (lovastatin or pravastatin)
Number of subjects: 6
Study 15110128 — intervention group
Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 6
Study 15110128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 6
Study 10931021 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60
Study 10931021 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study 9762211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (Group A): milk on day 1, mixed warm feeding on day 2, normal diet from day 3.
Number of subjects: 26
Study 9762211 — intervention group
Group type: COMPARATOR
Intervention: Nil by mouth until day 3 (Group B): milk on day 4, mixed warm feeding on day 5, normal diet from day 6.
Number of subjects: 26
Study 7824563 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral water temperature
Number of subjects: 30
Study 7824563 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred water temperature
Number of subjects: 30
Study 7824563 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow thermal changes
Number of subjects: 30
Study 7824563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid thermal changes
Number of subjects: 30
Study 3293873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg trimoprostil
Number of subjects: 8
Study 3293873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg trimoprostil
Number of subjects: 8
Study 3293873 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg trimoprostil
Number of subjects: 8
Study 3293873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31882016 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks (Control Group)
Number of subjects: 84
Study 31882016 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks + Palmijihwang‐hwan for 6 weeks (Treatment Group)
Number of subjects: 84
Study 31882016 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 84
Study 31882016 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Group
Number of subjects: 84
Study 29291695 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based therapy delivered by trained frontline workers
Number of subjects: 0
Study 29291695 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and implementation of evidence-based intervention
Number of subjects: 0
Study 29291695 — intervention group
Group type: COMPARATOR
Intervention: Crisis management responsibilities of case managers
Number of subjects: 0
Study 27515749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighbourhood socioeconomic position (NSEP) among non-diabetics
Number of subjects: 1789
Study 27515749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighbourhood socioeconomic position (NSEP) among pre-diabetics
Number of subjects: 1789
Study 24997748 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections, 2 injections during the first 2 weeks after injury.
Number of subjects: 145
Study 24997748 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control from a randomized trial with nonoperative treatment).
Number of subjects: 145
Study 23083956 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary distraction osteogenesis (DO)
Number of subjects: 0
Study 23083956 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthognathic surgery (CO)
Number of subjects: 0
Study 19454638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 100 x 10(6) autologous bone marrow‐derived mononuclear cells
Number of subjects: 50
Study 19454638 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study 17197401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-mechanical caries removal (CMCR)
Number of subjects: 50
Study 17197401 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 50
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x400 microg po every 3 h
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x800 microg po every 6 h
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x600 pv microg
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x800 microg po every 3 h
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x800 pv microg
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg pv wetted with saline repeated after 24 h if intact gestational sac
Number of subjects: 0
Study 16022846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x800 microg pv wetted with saline
Number of subjects: 0
Study 12238641 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30
Study 10443645 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 10 years
Number of subjects: 21
Study 10443645 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 21
Study 7805238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg TID)
Number of subjects: 22
Study 7805238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7805238 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% O2 administration
Number of subjects: 22
Study 7805238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 7805238 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 22
Study 2129678 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education course consisting of 3 informative-participative sessions
Number of subjects: 98
Study 2129678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study 478632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (H3ChN2Ch)
Number of subjects: 0
Study 478632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (Heq1N2Ch)
Number of subjects: 0
Study 478632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7043175 — intervention group
Group type: COMPARATOR
Intervention: Clopamide (5 mg/day)
Number of subjects: 17
Study 7043175 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopamide (5 mg/day) + Pindolol (10 mg/day)
Number of subjects: 17
Study 31961417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion sunscreen
Number of subjects: 48
Study 31961417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol spray sunscreen
Number of subjects: 48
Study 31961417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaerosol spray sunscreen
Number of subjects: 48
Study 31961417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump spray sunscreen
Number of subjects: 48
Study 31764094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 33
Study 27556931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Care Package Program for Relieving Hiesho (self-care program including wearing leg warmers, performing exercises, and pressing acupuncture points for 4 weeks)
Number of subjects: 140
Study 27556931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific actions taken)
Number of subjects: 140
Study 25622917 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious awareness of disgust images
Number of subjects: 0
Study 25622917 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal awareness of disgust images
Number of subjects: 0
Study 25622917 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral images in conscious condition
Number of subjects: 0
Study 25622917 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust images in conscious condition
Number of subjects: 0
Study 24439628 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric lenses (Medalist Fresh fit (PUREVISION 2 HD); Bausch+Lomb)
Number of subjects: 11
Study 24439628 — intervention group
Group type: COMPARATOR
Intervention: Spherical lenses (ACUVUE Oasys; Johnson & Johnson)
Number of subjects: 11
Study 24439628 — intervention group
Group type: COMPARATOR
Intervention: Comparison of spherical and aspheric lenses at different powers
Number of subjects: 11
Study 22368035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training (MS)
Number of subjects: 0
Study 22368035 — intervention group
Group type: COMPARATOR
Intervention: Matched-exposure control group (XP)
Number of subjects: 0
Study 19188394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cefepime, 2 g every 8 h (3-h infusion)
Number of subjects: 32
Study 19188394 — intervention group
Group type: COMPARATOR
Intervention: Model validation group
Number of subjects: 32
Study 19188394 — intervention group
Group type: COMPARATOR
Intervention: Initial model
Number of subjects: 32
Study 17898243 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual variant of cases
Number of subjects: 54
Study 17898243 — intervention group
Group type: COMPARATOR
Intervention: Baseline variant of cases
Number of subjects: 54
Study 14691438 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriership of the PlA2 allele in the highest fibrinogen quartile
Number of subjects: 455
Study 11802750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 11802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg 4 times a day)
Number of subjects: 537
Study 11802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg once daily)
Number of subjects: 537
Study 11802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily)
Number of subjects: 537
Study 11802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (misoprostol and lansoprazole)
Number of subjects: 537
Study 11802750 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 537
Study 11072388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 10
Study 11072388 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 8772218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin as prime in the heart-lung machine
Number of subjects: 60
Study 8772218 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of gelatin
Number of subjects: 60
Study 8772218 — intervention group
Group type: COMPARATOR
Intervention: Non-aprotinin patients
Number of subjects: 60
Study 2209907 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 99
Study 2209907 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anaesthesia
Number of subjects: 99
Study 7001056 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 40
Study 7001056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29786964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg/day
Number of subjects: 200
Study 29786964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 1.2 mg/day
Number of subjects: 200
Study 29786964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29786964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg on day 14
Number of subjects: 200
Study 27790791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) with 2 mA anodal tDCS over DLPFC
Number of subjects: 100
Study 27790791 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM with active stimulation during training
Number of subjects: 100
Study 27790791 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during training
Number of subjects: 100
Study 25573150 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with goniosynechialysis (PE+GSL)
Number of subjects: 22
Study 25573150 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone (PE)
Number of subjects: 22
Study 23413906 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopetidum (20 mg intramuscular injection, once every other day for 3 months)
Number of subjects: 156
Study 23413906 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy (control group)
Number of subjects: 156
Study 20938778 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 20
Study 19807760 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-particle NASHA gel
Number of subjects: 150
Study 19807760 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-particle NASHA gel
Number of subjects: 150
Study 19807760 — intervention group
Group type: COMPARATOR
Intervention: Both NASHA fillers (small and large particle)
Number of subjects: 150
Study 17325686 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (75 g/300 ml)
Number of subjects: 65
Study 17325686 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric sweetened drink
Number of subjects: 65
Study 15052514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics
Number of subjects: 86439
Study 15052514 — intervention group
Group type: COMPARATOR
Intervention: Typical neuroleptics
Number of subjects: 86439
Study 11848167 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption (mean daily intake of 66.5 ± 4.7 ml)
Number of subjects: 30
Study 11848167 — intervention group
Group type: COMPARATOR
Intervention: Alcohol restriction (mean daily intake of 10.2 ± 1.9 ml)
Number of subjects: 30
Study 10607247 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha (3 MU daily for 3 months followed by t.i.w. for 3 months)
Number of subjects: 149
Study 10607247 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha (3 MU t.i.w. for 6 months)
Number of subjects: 149
Study 10607247 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha
Number of subjects: 149
Study 10607247 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha
Number of subjects: 149
Study 10607247 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily IFN-alpha (for patients infected with HCV types other than HCV-1)
Number of subjects: 149
Study 10607247 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly IFN-alpha (for patients infected with HCV types other than HCV-1)
Number of subjects: 149
Study 7853632 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 45